Abstract
This paper argues, primarily by example, that mathematical modeling can contribute to harm reduction-orientated drug policy making in three ways: by contributing to quantitative evaluations of effectiveness, by improving data and understanding of the underlying drug-related phenomena, and by encouraging precise thinking about the goals and objectives of harm reduction.